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INTRODUCTION 
One of the most common cancers diagnosed in men is carcinoma prostate. Because 
of improvements in diagnostic testing, its incidence has been increasing. In patients 
with carcinoma prostate, ultra sonogram guided biopsy has been the investigation 
of choice in men with increased serum prostate specific antigen or a nodular 
prostate. Targeted biopsies will be helpful in increasing the sensitivity of 
systematic biopsy. 
Micro-bubble contrast agents are used as innovative technology to enhance 
detection of prostate cancer. Several studies have demonstrated that contrast 
enhanced ultrasound (CEUS) of prostatic blood flow helps in visualization of 
cancerous lesion and to target biopsy. Biopsy from target lesion helps in detecting 
more cancers with lesser cores .CEUS has been shown to detect cancers with 
higher Gleason scores, which improves cancer grading. 
Micro bubble contrast agent images the microvasculature in the prostate, especially 
in carcinoma, these contrast agents increase the sensitivity in detecting 
carcinomatous lesions. 
 We undertook this study to find the efficacy of CE sonography for detection of 
prostate in patients with PSA >4 ng/ml and compare this with conventional system. 
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AIM AND OBJECTIVE 
Primary objective: To assess the efficacy of contrast enhanced color Doppler 
ultrasound guided biopsy to detect prostate cancer. 
Secondary Objective: To compare prostate cancer detection with contrast 
enhanced ultrasound compared and conventional systematic biopsy and the impact 
on Gleason score. 
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REVIEW OF LITERATURE 
CARCINOMA PROSTATE 
Epidemiology 
 In men, carcinoma prostate is the most common malignancy with increasing an 
incidence over the past decade. The average age of diagnosis is 70 years and it 
occurs in 95% men between ages of 45-89 yrs. There is an exponential increase in 
incidence and mortality from prostate cancer after the age of fifty. Prostate cancer 
accounts for 2% of cancers in men younger than 50.There is 16.72% risk of disease 
in one’s lifetime and 2.57 % risk of death. A positive family history of prostate 
cancer increases the chance of the disease at an age younger than the persons 
without family history. Metastatic, incurable disease occurs in 50% of men with 
carcinoma prostate. To improve patient survival and to advocate a definitive 
treatment, early diagnosis of localized tumor is essential. 
RELEVANT ANATOMY: 
Prostate gland lies adjacent to bladder neck proximally and distally it is continuous 
with the membranous urethra. The adult gland weighs 18 to 20g. The gland 
measures about 3 cm in length, 4 cm in width and 2 cm in depth. The prostatic part 
of urethra traverses the gland closer to its anterior surface. The ejaculatory ducts 
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enter the base on its posterior aspect and run in an oblique fashion, terminating 
adjacent to the verumontanum.  
The prostate has an anterior, posterior and lateral surface with an apex inferiorly 
and base superiorly. The prostate is composed of 70% glandular elements and 30% 
fibromuscular stroma. McNeal separated the glandular prostate into four distinct 
regions. 
Central zone (CZ) 
It comprises about 25% of gland. The ducts of this region open around ejaculatory 
duct. This zone is responsible for 1-5% of adenocarcinoma. 
Peripheral zone (PZ) 
 This zone occupies the Postero-lateral aspect and forms bulk of the gland 
(70%).The ducts of this zone drain into prostatic sinus. It is responsible for 
Origin of up to 70% of prostate adenocarcinoma. 
Transitional zone (TZ) 
This zone accounts for 5-10% of prostatic glandular tissue.20% of prostate cancer 
arise from TZ. This is the commonest zone for BPH. 
Anterior fibromuscularstroma (AFS) 
This is the nonglandular portion and it is rarely invaded by carcinoma. 
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Fig 1 Zonal Anatomy of Prostate 
 
Fig 2 Diagrammatic representation of the prostate gland-Sagittal view. 
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ETIOLOGY: 
Genetics 
 Several variants in the chromosome 8 (8q24 region) ; Gene alterations on 
chromosome 1,X,17; BRCA-2mutations; germline mutations in HOXB13 ; PCAP 
gene; HPC1genearethe risk factors for prostate cancer. 
 
5-10 % cases may have familial predisposition .The risk of developing prostate 
cancer, increases with family history and they present about 6-7 years earlier.  
Diet  
Fat intake and obesity increases the risk.  
Hormones 
Androgens influence the development, maturation, and maintenance of the 
prostate, affecting both proliferation and differentiation of the luminal epithelium. 
Androgen exposure of the prostate plays an important role in prostate 
carcinogenesis. Eunuchs do not develop prostate adenocarcinoma, which is indirect 
evidence. Also, androgen ablation is one of the treatment option of prostate 
carcinoma.  
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5-alpha reductase 
 Studies shows an increased occurrence of prostate tumors of high-grade, in 
patients on finasteride or dutasteride compared with placebo. 
PATHOLOGY: 
                        Most (95%) are adenocarcinomas. 
                        About 4% are transitional cell carcinomas 
Fewer than 1% are squamous cell carcinomas. In many cases, squamous cell 
prostate carcinomas arise after hormone or radiation treatment.      
                       Neuroendocrine carcinomas (Rare) 
                       Synchronous occurrence of the multiple zones of the prostate gland 
commonly occurs and so most of them are multifocal.  
CLINICAL FEATURES: 
At present, most of the prostate cancers are seen in asymptomatic patients. 
Diagnosis in those cases is done based on screening of PSA levels or digital rectal 
examination findings. 
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Signs and symptoms: 
Symptoms of prostate cancer include: 
 Hematuria 
 Urinary complaints or retention 
 Back pain 
Physical examination alone could not accurately differentiate BPH from cancer. 
                In advance diseased patients, findings may include: 
 Bony tenderness 
 Cancer cachexia 
 Adenopathy 
 Lower-extremity lymphedema  
 Bladder over distension 
Local spread and metastasis: 
Prostate carcinomas are locally invasive. The peripheral-zone cancers extend into 
the seminal vesicles and ejaculatory ducts. 
The route of distant metastasis is not clear. The seed-and-soil theory, states that, 
“tissue factors may allow for preferential growth in some tissues, like bone”. The 
mechanical theory states that, “By direct spread through the venous spaces and 
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lymphatics , cancer can spread to the lumbar spine ”.  Prostatic capsule penetration 
and extension along the vascular or perineural spaces occurs at a later stage.The 
transitional-zone cancers spread to the bladder neck. 
Adrenal, liver, Lung metastases may occur.The bone metastasis can occur early, 
commonly without significant lymphadenopathy.  
The doubling time is longer than 4 years, in most cases. Only a few percentage of 
prostate carcinomas, double in less than 2 years. 
DIAGNOSTIC MODALITIES : 
Digital rectal examination (DRE)  
Prostate-specific antigen (PSA) measurement  
Transrectal ultrasound (TRUS)-guided prostate biopsy. 
Digital rectal examination: 
Early detection of prostate cancer  was based mainly on DRE before PSA era. DRE  
missed a substantial proportion of early cancer due to observer variability.There is 
an increased risk of prostate cancer in patients with abnormal DRE and so serum 
PSA and DRE  are used together for prostate cancer detection. 
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Screening: 
The American Cancer Society (ACS) recommends that, after discussion with 
themedical personnel about the risks, uncertainties, and benefits of screening, men 
must decide the option of screening for prostate cancer. 
 
The recommended age for screening is: 
 At an early age , with several first-degree relatives with prostate carcinoma- 40 
years of age  
 Before  65 years of age with a  first-degree relative with prostate cancer and for  
African Americans - 40 or 45 years of age  
 With at least a 10-year life expectancy and  at average risk - 50 years of age  
 
The USPSTF (US Preventive Services Task Force) is against any routine PSA-
based screening for prostate tumors. This recommendation, is however considered 
controversial. 
Prostate Cancer Screening: 
The two main components used in prostate cancer screeningare DRE and PSA 
evaluation .Transrectal ultrasonography (TRUS) has established a major role in 
directing prostatic biopsies , but it may have a high false positive rates. 
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Prostate-Specific Antigen: 
When PSA testing was first used, the upper limit of normal was thought to be 
4ng/mL. However, subsequent studies indicate that there is no absolute PSA level 
that guarantees the absence of prostate cancer. The risk of this disease increases, as 
the PSA level increases. 
When the level is 1 ng/mL, cancer is seen in about 8% of men. When the PSA 
level is about 4-10 ng/mL, prostate cancer is detected in about 25%; with a level > 
10 ng/mL, the chance is much higher. 
A cutoff value of PSA of 3 ng/mL or higher as an indication for sextant biopsy,is 
placed by ERSPC (European Randomized Study of Screening for Prostate Cancer) 
. 
Shao et al suggested that in the absence of any method to distinguish aggressive 
from indolent cancers, lowering the PSA cutoff might increase the chance of 
overdiagnosis and overtreatment. 
  Many approaches have been made to improve the accuracy of PSA to detect the 
prostate cancer. These include PSA velocity level and the free PSA percentage. 
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Factors Influencing PSA: 
 Age 
 Race 
 Prostate volume. 
 Androgens 
 Metabolic factors -Obesity 
 Presence of prostatic disease  
Any architectural disruption in normal prostate allows PSA to gain access into 
circulation leading to elevations of serum PSA.  Elevated PSA occurs in diseases 
like BPH, prostatitis, prostate cancer and prostatic manipulation. Prostate directed 
treatments decrease the volume of prostatic epithelium available for PSA 
production and decreases the amount of PSA produced per cell. Both type 1 and 
type 2 5α-Reductase inhibitors used for BPH treatment lowers PSA levels. 
Clinical use of PSA: 
The serum PSA level indicates measurement of both free PSA and complexed 
PSA. (ACT) .The detection of  organ confined prostate cancers is increased by the 
use of PSA. The prostate cancer detection on biopsy increases directly with PSA 
level. Detection rate of prostate cancer and detectionof cancers with a more 
favorable prognosisis increased by combined PSA and DRE. 
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PSA velocity:   
To calculate velocity, at least 3 consecutive measurements over a period of, at least 
18-24 months should be used. Guidelines from the National Comprehensive 
Cancer Network recommend that PSA velocity be considered in the context of the 
PSA level. 
The PSA velocities that is suspicious for cancer: 
 PSA velocity of 0.75 ng/mL/y, when the PSA is 4–10 ng/mL. 
 PSA velocity of 0.35 ng/mL/y, when the PSA is ≤2.5 ng/ml. 
Vickers et al in 2011 questioned the PSA velocity concept. In his study, PSA 
velocity levels, with a comparable specificity to PSA level levels, showed a lower 
sensitivity, particularly for high-grade cancers and clinically significant prostatic 
tumors. He concluded that, “PSA velocity would add little to the predictive 
accuracy of positive DRE or high PSA levels and would significantly increase the 
number of men recommended for prostatic biopsy”. This controversy has not been 
resolved. 
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Bound versus free PSA:  
The measurement of bound and free PSA can help to differentiate cancer from 
benign prostatic hyperplasia. Free PSA is calculated as a % of total PSA. 
 A recommendation for or against prostatic biopsy in men with a PSA level of 4-10 
ng/mL can be done based upon free PSA percentage. When the free PSA 
percentage  is lower, then there is a higher  likelihood of cancer. 
Typically, a free PSA > 25% is taken as normal. Some investigators recommend 
prostatic biopsy when the free PSA is < 18%; other expertsadvise a cutoff value of 
12%. Many investigators however recommendsthat prostatic biopsy, in men with a 
PSA level of 4-10 ng/ml, can be done without any additional free-PSA test.  
Transrectal ultrasound (TRUS)-guided prostate biopsy  
TRUS and PROSTATE 
NORMAL SONOGRAPHIC APPEARANCE: 
 Images are shown as if one stands at the feet of a supine patient and looks headward. 
The rectum is displayed at the bottom of the screen, with the ultrasound beam arising 
from within the rectum. In transverse section, left side of the patient is seen on the 
image right side, with anterior abdominal wall on the top of the screen. In sagittal 
section, on the image left side, the head side of the body is located. 
 
 
15 
Axial Ultrasound Anatomy: 
The seminal vesicles are seen as bilateral hypoechoic, multiseptated structures at 
the level superior to the base of the prostate gland. The vas deferens is situated 
posterior to the seminal vesicles and they enter the prostate at midbase, where they 
join to form the ejaculatory ducts. The two ejaculatory ducts finally open into the 
verumontanum. The peripheral zone is uniformly homogeneous and is slightly 
more echogenic than the transition zone. The peripheral zone echogenicity is 
commonly taken as the standard for echogenicity in the prostate gland  and is said 
to be isoechoic.The margin of the prostate gland is sharp except in the region 
posterolaterally where the neuro vascular bundles enters the gland making the 
margin blurred. 
 
Fig 3Axial Sonographic Examinations of The Prostate Gland 
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A, Axial image above base showing the seminal vesicles (SV) and vas deferen(V); 
B, bladder.B, Axial scan at the mid glandular level. The normal hypoechoic 
muscular internal urethral sphincter is shown as horizontal arrowsand the 
ejaculatory ducts (vertical arrows). C, Axial scan at the lower third of prostate 
shows urethra (U) as hypoechoeic region. Most of the visible gland at this level is 
peripheral zone. The posterolateral aspects (arrows) have an irregular outline, due 
to the entrance of the neurovascular bundles. D, Axial scan just below apex of 
prostate showing the cross section of distal urethra (U).Pelvic sling muscles are 
visible (arrows). 
Sagittal Ultrasound Anatomy: 
On midsagittal view, the hypoechoeic muscular internal urethral sphincter can be 
seen extending from the bladder to verumontanum. The anterior fibromuscular 
zone forms an ill defined area anterior to the internal sphincter.  At the 
verumontanum, the distal urethra angulates slightly anteriorly and finally exits the 
apex of the gland. In the mid plane the ejaculatory ducts are seen as hypoechoic 
tracts running from the vas deferens to the centrally located verumontanum. Para- 
sagittally, the anterior transition zone can be seen separated from the posteriorly 
lying peripheral zone by the surgical capsule. The seminal vesicles and vas 
deferens are seen above the base. 
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Fig 4 Sagittal  Sonographic View Of Prostate Gland 
 A, Mid sagittal view showing the internal urethral sphincter (white arrows), with 
the echogenic collapsed urethra (*). The ejaculatory ducts (E) runs from the vas 
deferens (V) to the verumontanum (oblique arrow). B, Mid sagittal view at base 
showing the vas deferens (V) and adjacent seminal vesicles (S) as they are entering 
the prostate gland.C, Parasagittal view showing the lateral prostate, as 
homogeneous and isoechoic structure occupying almost totally of peripheral zone 
tissue; SV, seminal vesicle.D, Parasagittal view above the prostate showing the 
seminal vesicles (SV)and vas deferens(V)at the level above the prostate (P). 
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Method of scanning: 
The patient is made to lie in a left lateral decubitus position for the scanning. 
Rectal cleansing by self administered enema is generally done before the scan. 
Laxatives may be given in patients who cannot administer the enema. It is must to 
do a digital rectal examination before inserting the probe to make sure no rectal 
abnormalities that will interfere with safe probe insertion. After lubrication, the 
transrectal probe is gently inserted into the rectum. To lessen the discomfort, 
lidocaine gel is be used as the lubricant in patients with tight sphincters or anal 
pathology such as hemorrhoids or fissures. End-fire probe may be inserted by 
direct vision to follow the curve of the rectal canal and lessen patient discomfort.  
When examining the prostate gland, a systematic approach works best. First the 
prostate is scanned in gray scale with representative images taken, in the axial 
plane, from the base, to the urethral level at the apex, then secondly in the sagittal 
plane, from right lobe to mid plane to left lobe. Then, the scanning is done with 
Doppler imaging in the axial plane to allow evaluation of vascular symmetry.   
Measurements are then taken: axial width (W; right to left), anteroposteriorly (AP; 
anterior midline to rectal surface), length (L; head to foot). Prostate volume is 
measured with the formula: volume = 0.5236 *(W *AP*L) 
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Transrectal ultrasound is used in prostate cancer  
 To Guide biopsy  
 To Guide therapy 
 To Measure volume  
Indications for Prostate Biopsy : 
1. Abnormal DRE.  
2. PSA of 10 ng / mL or greater. Some studies reduced the PSA criterion to 4 or 
sometimes even 2.5 ng / mL. 
3. Nodule seen at TRUS.  
4. High PSA velocity.  
5. Positive chips at TURP.  
6. Males with metastatic adenocarcinoma, with undetermined primary. 
Contraindications to Prostate Biopsy 
 Significant coagulopathy 
  Painful anorectal conditions 
 Severe immunosuppression 
  Acute prostatitis  
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Preparation: 
At the same visit, it is required to prepare for both TRUS and biopsy .If benign 
cause is found on TRUS, biopsy can be avoided. 
Informed consent must be done. A broad-spectrum antibiotic like quinolones 
(ciprofloxacin) is given, one dose an hour before and after the biopsy for several 
days. In patients who are using anticoagulation agents biopsy should not be done , 
until these drugs have been stopped for several days, depending on the drugs. 
Aspirin-induced coagulation abnormalities are not severe enough to avoid safe 
biopsy. Biopsy is not to be done during urinary infections. It is necessary to wait 4 
to 6 weeks for symptoms to subside and to confirm antibiotic sensitivities to 
appropriate prophylaxis for biopsy. Before doing prostate biopsy, endocarditis 
prophylaxis for genitourinary procedures is no longer required, in patients with 
valvular heart disease. 
Technique: 
The patient is made to lie in the decubitus position. A DRE is done before inserting 
the probe to palpate the prostate and to make sure that probe insertion will be safe. 
Insert the probe with needle guide attached at the outset to save time and examine 
the prostate. Local anesthesia decreases the discomfort of the biopsy. By direct 
injections of the anesthetic drug into the gland, anesthesia may be virtually 
instantaneous in most of the patients. Anesthetic gel can also be used.  
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The automatic biopsy gun with 18-gauge needles will have good patient 
acceptance and safety. By using the targeting line, the probe and contained 
needle can be moved to the target. Then, a simple, swift motion is done to 
advance the gun and needle tip to the surface of the lesion. Once they are in 
position, the device must be triggered and the needle should be advanced for 
approximately 2 to 3 cm. First, the inner stylet advances, and then, finally the 
outer sheath advances to get the tissue core and it traps it in the beveled portion 
of the inner needle. 
 
Mechanism of needle function .1. Advancing the closed needle to the lesion. 2. 
By triggering, stylet of the inner chamber enters the lesion. 3. Finally the outer 
sheath enters and cuts off and acquires the sample. 
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First sample suspicious areas, in patients who cannot tolerate the entire procedure, 
and finish with systematic sampling. It is must to avoid biopsy through the 
ejaculatory ducts, urethra and internal urethral sphincter because it may lead to 
considerable urethral bleeding and major injury to those structures. After removing 
the probe out, the site is palpated for hematomas, and if it is present, finger 
pressure must be applied for approximately a minute to stop bleeding. After 
finishing the procedure , the patient must be kept for an hour and in that the first 20 
minutes in lying down posture and the remainder seated. This prevents problems 
which are caused by the late onset of vasovagal complications 
 
Fig 5 Biopsy Protocol 
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Number of samples and locations of prostate biopsy: 
 The number and locations are controversial. Initially only suspicious areas are 
thought to be sampled. It was later found that only about 50% -70 % of hypoechoic 
regions contained cancer, and that cancer may also be present in normal-looking 
areas of the prostate. Therefore “targeted + systematic” sextant (six-core) biopsy is 
done. 
Subsequently, increased numbers of biopsy samples have been suggested as about 
30% of cancers were not diagnosed by the sextant biopsy. So, ten to 12 cores are 
held to be appropriate on the initial visit. 
So at the initial visit , suspicious hypoechoic areas are sampled first, then a 
systematic 10 to 12–core pattern of biopsy is done. Typically, samples are taken 
from the peripheral zone at the apex, middle and base of the prostate gland, both 
medially and laterally of each lobe.  
 
A – sextant biopsy (Hodge et al) 
B – 10 core biopsy (Presti ) 
C – 12 core biopsy 
D – 13 core biopsy (Eskew 
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Side Effects and Complications: 
 Minor side effects like bleeding in urine, sperm, and stool may be common and is 
seen in most of the patients after transrectal biopsy. Major complications due to 
prostate biopsy that may require further intervention have been low, about 1% to 
2%, which are independent of the needle size, or approach or mode of guidance. 
These significant complications include large hematoma, significant rectal 
bleeding, urinary retention and sepsis. After using prophylactic antibiotics, the 
incidence of septic complications is reduced to about 1%.  
Color and Power Doppler Imaging 
Doppler imaging is being used for detection of neovascularity associated with 
prostate cancer. This approach is especially useful to find isoechoic cancer because 
of the fact that pathology of these cancers show to have increased microvessel 
density. The hypoechoic sites that are vascular tend to have more tumor volume 
and higher Gleason score when evaluating biopsy. The power Doppler mode is 
more sensitive to detection of flow, gives a uniform display of vascular density, 
and gives images that are stable at different machine settings. There are some 
limitations with Doppler imaging. That is not all cancers are vascular. The absence 
of vascularity should not be taken as a point in deciding against the biopsy of a 
suspicious nodule and biopsy should be done in it. 
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Elastography 
Prostate cancer areas are stiffer than areas with benign tissue. Areas containing 
cancer can be detected, but at present the overall detection is almost similar to 
systematic biopsy, and this procedure could not be used to avoid biopsy. Increased 
resistance has been found in chronic inflammation and atrophy also resulting in 
false postivity. Elastography would have a long learning curve wit high subjective 
nature and also those images are difficult to reproduce. New techniques using 
sound waves to produce tissue strainare developed to avoid variations seen with 
the technique of manual compression. 
 Contrast-Enhanced Ultrasonography and Targeted biopsy 
The disadvantages of conventional B-Mode and colour Doppler ultrasound can be 
overcome by ultrasound contrast agents (UCA), which act as blood pool tracers 
and enable us to display the parenchymal microvasculature.  
 Ultrasound contrast agents remain in the intravascular space, but the most of the 
CT and MRI contrast agents are usually rapidly sent into the extracellular space, 
from the blood pool. 
Multiple advantages of contrast ultrasound lies in its ability to assess dynamically 
about the contrast enhancement patterns in real time, as well as the possibility of 
performing repeated sonographic examinations. 
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The dynamic enhancement of the lesion is visualized either during intermittent or 
continuous scanning, but it depends on the contrast agent used and ultrasound 
mode. 
ULTRASOUND CONTRAST AGENTS :(UCA) 
First Generation UCA-Non Trans Pulmonary Vascular 
Second Generation UCA-Trans Pulmonary, Vascular,Shory Half Life 
Third Generation UCA-Trans Pulmonary, Vascular, Longer Half Life 
UCAs have a micro bubble structure with gas bubbles which are stabilised by a 
shell. SonoVue is a second generation contrast agent with Phospholipid-stabilized 
microbubbles, with Sulfur hexafluoride gas. 
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Dose:  
One ml of sonovue has 8 μl of sulphur hexafluoride micro bubbles, equivalent to 
45 micrograms. Dose required - B-mode imaging cardiac chambers, at rest or with 
stress requires 2 ml. For vascular Doppler imaging it is about 2.4 ml. In children < 
18 years, the effectiveness and safety of this agent is not established and hence 
should not be used. 
At clinical doses usually used, SonoVue produces marked increase in signal 
intensity for 3 to 8 minutes for microvasculature and macrovasculature Doppler 
imaging; and > 2 minutes for grey scale imaging. 
Preparation and administration: 
 The contents of the vial are injected into 5 ml of sodium chloride 0.9%), for 
preparation of the contrast dispersion. The lyophilisate is dissolved completely, by 
shaking the vial vigorously for few seconds. For up to six hours after reconstitution 
, the dispersion of desired volume, can be drawn into a syringe. 
SonoVue is injected into a peripheral vein, immediately, after it is drawn into the 
syringe . A 5 ml of sodium chloride (0.9%) flush is done after each injection. 
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Pharmacokinetic properties: 
For the clinical dose, the amount of sulphur hexafloride gas injected is very small 
(16 μl of gas in a 2 ml dose). The gas, after dissolving in the blood, is exhaled 
through the lungs. The half-life of this agent was about 12 minutes. Within 2 
minutes after injection, more than 80% of the gas administered, was exhaled and 
after 15 minutes, nearly 100% is exhaled. 
Contraindications: 
 History of hypersensitivity to UCA (sulphur hexafluoride). 
 Evolving myocardial infarction, 
 Acute cardiac failure,  
 Recent coronary artery intervention, 
 Pulmonary hypertension (severe), 
 Severe rhythm disorders, 
 Right-to-left shunts,  
 Significant worsening of cardiac symptoms, 
 Adult respiratory distress syndrome, 
 Class III/IV cardiac failure,  
 Angina at rest (within last 7 days),  
 Pregnant and lactating women, 
 Uncontrolled systemic hypertension. 
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Management: 
Localized prostate cancer: 
                  For clinically localized prostate cancer, standard treatment includes: 
 Active surveillance 
 Androgen deprivation therapy (ADT) 
 Radical prostatectomy 
 Radiation therapy 
Metastatic prostate cancer: 
Metastatic prostate cancer is not curable, and these cases are managed by: 
 Therapy for relief of particular symptoms (eg, pain palliation) 
 Measures to slow any further progression of the disease 
Prognosis: 
The Gleason grade, the margin positivity or capsular penetration (at the time of 
prostatectomy) and the tumor volume are the most important prognostic indicators 
for prostate cancer. High-grade prostatic carcinoma is often found with adverse 
pathologic findings and disease progression. 
Seminal vesicle invasion and high-grade cancer are the main determinants of 
prostatic tumor–specific mortality. 
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The CAPRA (Cancer of the Prostate Risk Assessment) score for calculating 
prognosis is analyzed by: 
 Age at diagnosis 
 Gleason score 
 PSA level 
 Percentage positive biopsy cores  
 Clinical tumor stage 
This score is well accurate for predicting mortalities and metastases.
 
Molecular prognostic markers: 
Several molecular markers were studied for determining the prognosis of patients, 
who are under treatment for localized as well as metastatic prostate cancers. 
 
 At present, none of them are measured in routine practice. 
Morbidity and mortality: 
It is the second most common etiology of cancer death in men, after lung 
carcinoma. Death rates have significantly decreased due to diagnosis of 
progressive disease at an earlier stage and also by improvements in the treatment of 
late stage disease. 
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Radical prostatectomy and radiation therapy leads to permanent side effects like 
urinary incontinence and erectile dysfunction. 
Radiation therapy given for prostate cancer may lead to secondary malignancy, 
such as bladder cancer and rectal cancer. 
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MATERIALS AND METHODS 
TITLE OF THE STUDY 
 Comparison of Contrast Enhanced Color Doppler Targeted Biopsy To 
Conventional Systematic Biopsy In Carcinoma Prostate. 
TYPE OF STUDY 
Prospective   study 
PERIOD OF STUDY   
January 2013 – February 2014 
PLACE OF STUDY 
The study was conducted in Department of Urology and Radiology, Madras 
Medical College and Rajiv Gandhi Government Hospital , Chennai – 3 
ETHICAL CLEARANCE 
The institutional ethical review board at our hospital approved the study (No: 
35032013) 
INCLUSION CRITERIA  
Patients with serum prostate specific antigen > 4 ng/ml 
Normal or abnormal digital rectal examination 
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EXCLUSION CRITERIA  
1. Active UTI  
2. Prostatitis  
3. Un Co-Operative Patients 
4. Allergy to ultrasound contrast agents 
5. Contra-indications to ultrasound contrast agents like -Recent acute 
myocardial infarction (< 7 days), Right-to-left shunts, Class III / IV cardiac 
failure, and severe pulmonary hypertension. 
METHOD OF STUDY 
Informed consent was obtained from all the patients. The patients were started on 
prophylactic antibiotic the night before biopsy. on the morning of biopsy, a 
cleansing enema was given for the patient. Aspirin or nonsteroidal anti-
inflammatory agents are withheld for at least 5 days before biopsy.  
Transrectal ultrasound examination of the prostate, TRUS examination during 
infusion of contrast material, and biopsy of the prostate are all done during a single 
visit.  Transrectal sonography was performed with Siemens ultrasound machine for 
all patients. Contrast enhanced sonography was done using sonovue, as the 
ultrasound contrast agent. The lyophilized powder is shaken with 5 mL of distilled 
water for 20 sec. By using a 20-gauge cannula, 1.5 ml contrast agent bolus was 
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injected into the left antecubital vein manually.  1 ml solution contains 8ug/ml. 5 
ml of normal saline is injected each time, after injecting the ultrasound contrast 
agent.  
With a mechanical index of 0.6–1.2, contrast enhanced ultrasound was done, after 
contrast agent injection intravenously. 20 seconds of inter sweep delay were given, 
to prevent the unnecessary destruction of micro bubbles. From the prostatic base to 
the apex, contrast ultrasound was done. Each scan requires 5 to 10 sec depending 
upon the prostate volume. The entire imaging performed was repeated during 
infusion of contrast material. These images were obtained finally stored in digital 
format for further interpretation. 
Targeted core biopsy is taken from contrast enhanced areas after administration of 
UCA. To avoid hyperemia produced by biopsy, contrast enhanced scanning is 
always done before systematic biopsy. Transitional zone is not biopsied  
 
 
 
 
 
 
Fig 6 US Contrast Agent Sonovue 
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Subsequently, the same patient underwent systematic biopsy from 8 sites after 
imaging protocol. The prostate gland is divided into eight sites. They are apex; 
base; medial; and lateral portions of the mid gland, on the right and left sides. 
Biopsies were obtained using an 18 gauge biopsy needle. Ultrasound examination 
and biopsy takes about 30–40 minutes for each patient.  Eight biopsy samples from 
each patient were sent in eight bottles separately, according to biopsy site for each 
patient. Biopsies were obtained without regard to prostate US appearance. In each 
biopsy specimen, the histopathological study was done to detect the presence of 
cancer foci and gleason grading was assigned to each core of biopsy. 
 The biopsies from contrast enhanced areas are sent separately  and  examined 
histopathologically for the presence of cancer foci and corresponding Gleason 
grading assigned.  
 In this study, 25 patients were biopsied. So, totally 25 x 8=200 sites were biopsied 
totally in these 25 patients. Also ,total biopsy cores from contrast enhanced sites 
from these 25 patients was 35.The number of patients were less but the number 
biopsy sites were very large , so this study is not limited by the number of samples. 
Pathologic evaluation of the biopsy cores was the reference standard for 
calculation of sensitivity and specificity. The cancer detection rates of the 2 
techniques and the Gleason scores between two techniques were compared. 
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Using Paired T test, specificity, sensitivity for prostate cancer detection was 
analyzed. Chi square test and ROC curve analysis were used. 
In all the above statistical analysis, a p value of < 0.05 was considered significant. 
 
Ultrasound machine (Siemens Antares), Probe and Biopsy gun and Kit . 
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OBSERVATION AND RESULTS 
Our study consists of 25 patients who are suspected to have carcinoma prostate 
either due to elevated serum PSA or abnormal digital rectal examination or both. 
AGE DISTRIBUTION OF CASES 
The subjects ranged in age from 41 – 80 years with a mean of 62.2 years. 
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PATIENT CHARACTERISTICS 
Sixteen patients were included due to presence of both abnormal DRE and elevated 
serum.PSA>4 ng/ml. Two patients had only abnormal DRE with normal serum 
PSA. Seven patients had an elevated serum PSA alone with a normal DRE. 
 
 
A total of 35 cores were taken from contrast enhanced areas out of which 26 cores 
were positive for malignancy. Out of 200 cores taken by systematic biopsy, 30 
cores were positive. Separate Gleason score was given to each of the cores from 
contrast enhanced areas as well as systematic biopsy cores. 
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Gleason score distribution in contrast enhanced biopsy vs systematic biopsy 
Biopsy from contrast enhanced areas showed a gleason score of 8 in 2 patients, 
seven in 9 patients, six in 3 patients, five in 6 patients and three in one patient. out 
of 25 cases,21 cases were positive for malignancy by contrast enhanced biopsy and 
4 patients were negative for cancer. Out of this 4 patients,3 were BPH and 1 
showed high grade PIN. 
In the systematic biopsy group, a gleason score of 6 and 7 were present in 4 
patients each, a score of 5 in 7 patients and 3 in 2 patient. 
 
 
0
1
2
3
4
5
6
7
8
9
3 5 6 7 8
1 
6 
3 
9 
2 2 
7 
4 4 
ceus bx
syst.bx
 
 
40 
 
Higher grade cancer (Gleason score 7 or greater) was more common in patients 
with a positive targeted biopsy.
 
Dot-and-Line diagram 
Systematic biopsy vs CEUS guided biopsy 
 
 Analysis by Paired samples t-test  of gleason scores between systematic and 
contrast enhanced biopsy  showed a 95% CI of 0.22 to 1.11 with a significant  p  
value (p=0.0032). 
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Distribution of positive cores in contrast enhanced biopsy and systematic 
biopsy : 
Prostate cancer were detected in the base (n = 6), mid gland (n=15), Apex (n=5) in 
contrast enhanced biopsy. In systematic biopsy, cancers were detected in base      
(n =5), mid gland  (n =21 ),apex (n=4). 
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ULTRASONOGRAPHIC FINDINGS VS BIOPSY RESULTS  
      Findings at USG Negative cores Positive cores 
Baseline TRUS   
         NEGATIVE          156             18  
          POSITIVE           14              12 
Contrast enhanced TRUS   
         NEGATIVE          5  - 
          POSITIVE          4   26 
  
Sensitivity and specificity for detection of prostate cancer was calculated using 
pathology of biopsy cores as reference standard. For baseline TRUS ,sensitivity 
was 40 %  (12 /30) with specificity of 91.7%(156/170).For contrast enhanced 
ultrasound, sensitivity was 100 % (26/26) but specificity was 56%(5/9).Chi square 
and Exact Measures of Association showed a significant P value <0.0000001. 
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Standard TRUS and Contrast-Enhanced ultrasonography by Biopsy Site in 25 
Patients: 
 
 
Of the 25 patients evaluated, 21 patients showed positivity for prostate cancer by 
contrast enhanced TRUS biopsy. (84%).But systematic biopsy demonstrated 
cancer in 17 patients  only out of the 25.( 68%). 
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Sensitivity of contrast enhanced TRUS with respect to serum PSA: 
Our study included patients with serum PSA values  ranging from 0.6 – 24.06 
ng/ml with a mean of 12.73 .ROC analysis of sensitivity of contrast enhanced 
TRUS in relation to serum PSA showed  area under curve of  0.863095 and  
95% Confidence interval of 0.666917 to 0.966550 with a significant P value of  
<0.0001. 
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CASES 
CASE 1: 
65 years male with urgency and hesitancy while passing urine past one year, 
with PSA level 9.1 ng/ml. Gray scale shows a nodule in left mid portion 
medially, laterally; left base and right base. Color Doppler shows increased 
vascularity in left mid portion medially, left apex. Contrast ultrasound shows 
increased enhancement in left base, apex, left mid portion medially, 
laterally, right base, right mid portion medially. HPE shows cancer in left 
base, apex, mid portion medial, lateral, right base.
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Case 2: 
 62 years came with complaints of difficulty in passing urine and urgency past 6 
months. His PSA level was 8.2 ng/ml. Lesion noted in the left base of the prostate, 
with focal enhancement on contrast ultrasound, was not seen in gray scale and 
color Doppler, which finally turned out to be cancer on HPE 
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DISCUSSION 
For diagnosing prostate cancer, Transrectal ultrasonogram guided prostate 
systematic biopsy is the standard technique. Only a few studies were conducted in 
the past decade to analyze the efficacy of contrast enhanced ultrasound imaging for 
diagnosis of prostate carcinomas .Various studies gave different results, while 
analyzing the merit of contrast agent in prostate cancer. That too, most of the 
previous studies were done in patients with high prostate specific 
antigen(PSA),with only a few studies done in patients with indeterminate PSA 
levels , as the impact of diagnosing prostate cancer with ultrasound contrast agent 
will be much better appreciated if studies were done in those population.  
Ethan J. Halpern, Ferdinand Frauscheret al study was,  
“The value of the Ultrasound contrast targeted biopsy of the prostate gland cancer. 
Forty patients were examined with contrast agent, by using continuous intravenous 
infusion and following bolus of perfluteren microspheres. Cancer was detected in 
30 biopsy samples in 16 of the patients.(40%).It was concluded that a suspicious 
site identified during contrast-enhanced sonography was 3.5 times more chance to 
have positive biopsy findings compared to an adjacent site that was not suspicious 
of cancer (p < 0.025). When a cancer suspected site was examined with an 
additional biopsy core, that site was diagnosed to have five times more likely to 
have a positive finding of cancer than the usual standard sextant site (p < 0.01). 
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They have found no significant difference in diagnostic accuracy between bolus 
and continuous infusion of contrast material.” 
               Michael Mitterberge, WolfgangHorninger et al study[73] was, “A 
Randomized prospective trial comparing contrast-enhanced ultrasound targeted 
biopsy cores with gray-scale US guided systematic biopsy cores to determine their 
efficacy of the cancer detection rate. Cancer was found in 16 out of 50 subjects 
(32%) by targeted biopsy, and in 13 out of 50 patients (26%) with systematic 
biopsy. The cancer detection rate by targeted biopsy was significantly better than 
the systematic gray scale approach (P < 0.04, McNemar). The rate of cancer 
detection by using targeted biopsy cores (15.6% or 39/250 cores) was much 
significantly better than by using systematic core samples (6.8% or 34/500 cores, P 
< 0.001, McNemar). Contrast sonography targeted biopsy can detect more cancers 
than systematic biopsy with less number of biopsy cores.” 
In our study of 25 men, cancer was detected by CEUS and SB in 21(84%) and 17 
(68%), respectively. The rate of detection of cancer by targeted biopsy was 74.2% 
or ( 26 of 35 cores)  whereas the detection rate  for systematic biopsy  cores was 
15% or( 30 of 200).  Cancer was missed in 4 patients (11.2%) which may be due to 
the fact that targeted biopsy were not taken from TZ cancers. 
 Operator dependence seems to be higher for the targeted technique than for the 
systematic one.  
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The appearance of microvessels in benign hyperplasia of prostate is very difficult 
to differentiate from those in cancer prostate. It might be possible that with new 
techniques, such as dynamic assessment of contrast agent enhancement, this 
problem will be overcome. However, this must be evaluated in further studies. 
We performed 8 systematic and 1 core each from contrast enhanced area as 
targeted biopsies, which is completely different than a study design comparing 
10 vs 15 cores. It has been demonstrated that multiple cores from single 
hypervascularized area were more likely to detect cancer than fewer less cores.  
Prostatitis may be associated with multiple hypervascularized areas .The main 
advantage of contrast enhanced TRUS is that it enhances areas of cancer which are 
not usually picked up by standard gray scale USG or those areas missed by 
systematic biopsy. 
Our study demonstrates that contrast enhanced transrectal sonography,   showed a 
statistically significant advantage for the detection of prostate cancer compared 
with conventional non-enhanced sonography. Contrast enhanced transrectal 
sonography is  doubly sensitive than  baseline sonogram for detection of prostate 
cancer with no substantial loss of specificity. There is a significant improvement in 
diagnostic accuracy with enhanced imaging, as shown by ROC analysis . It is clear 
from our study that contrast enhanced ultrasound picks up high grade lesions than 
regular TRUS biopsy. 
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The tumor grade, stage, volume, and microvascular density of carcinoma prostate 
are important from a clinical stand point. Persons with gleason score of two to four 
showed normal life expectancy when managed conservatively. Watchful waiting 
had a favourable prognosis in localized prostate cancer, according to a prospective 
study. So it is important to identify tumours in early stage to improve survival and 
treatment outcomes in patients with carcinoma prostate. Also unnecessary 
overtreatment should also be avoided. 
Out of 25 patients, in our study, 21 were demonstrated to have cancer by both 
contrast enhancement and corresponding positive biopsy cores. The lesions shown 
in contrast enhanced cores were of higher gleason grade when compared to 
systematic biopsy. 
We took a total of 200 biopsy cores from 25 patients by conventional TRUS 
examination. Out of these 200 cores, only 30 cores were positive for malignancy 
indicating the need for more number of cores for detecting lesser cancers. Biopsy 
from target lesions helps in identifying more cancers of higher grade in lesser 
cores, thereby decreasing complications of biopsy. 
The identification of higher grade cancers in targeted biopsy in the same patients 
who have a lower grade due to regular biopsy has a significant impact on 
treatment. 
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Conclusion 
The results of this study shows that 
 The sensitivity and accuracy of cancer detection is improved by using ultrasound  
contrast agents for depicting microvessels in carcinoma prostate. 
The use contrast agents in TRUS will help in targeted biopsy of the enhancing 
lesions thereby decreasing the number of biopsy cores and associated 
complication. 
The use of CEUS also may be useful in patients with indeterminate serum PSA. 
Targeted biopsy has a definite impact on gleason scores, detecting high grade 
cancers with limited number of cores thus helping in planning the treatment in 
carcinoma prostate. 
 
 
 
 
 
 
 
52 
Bibliography 
1 Alexandre Pelzer Et Al Prostate Cancer Detection In Men With Prostate 
Specific Antigen 4 To 10 Ng/Ml Using A Combined Approach Of Contrast 
Enhanced Color Doppler Targeted And Systematic Biopsy, The Journal Of 
Urology  Vol. 173, 1926–1929, June 2005 
2 Hodge, K. K., McNeal, J. E., Terris, M. K. and Stamey, T. A.:Random 
systematic versus directed ultrasound guided transrectal core biopsies of the 
prostate. J Urol, 142: 71, 1989 
3 Eskew, L. A., Bare, R. L. and McCullough, D. L.: Systematic 5 region 
prostate biopsy is superior to sextant method for diagnosing carcinoma of 
the prostate. J Urol, 157: 199, 1997 
4 Stewart, C. S., Leibovich, B. C., Weaver, A. L. and Lieber, M. M.: 
Prostate cancer diagnosis using a saturation needle biopsy technique after  
previous negative sextant biopsies. J Urol, 166: 86, 2001 
5 Newman, J. S., Bree, R. L. and Rubin, J. M.: Prostate cancer:diagnosis with 
color Doppler sonography with histologic correlation of each biopsy site. 
Radiology, 195: 86, 1995 
6 Bree, R. L.: The role of color Doppler and staging biopsies inprostate cancer 
detection. Urology, 49: 31, 1997 
 
 
53 
7  Cosgrove, D.: Ultrasound contrast enhancement of tumours. ClinRadiol, 
suppl., 51: 44, 1996 
8 Blomley, M. and Cosgrove, D.: Microbubble echo-enhancers: a new 
direction for ultrasound? Lancet, 349: 1855, 1997 
9 Norberg, M., Egevad, L., Holmberg, L., Sparen, P., Norlen, B. J. and 
Busch,C.: The sextant protocol for ultrasound-guided core biopsies of the 
prostate underestimates the presence of cancer. Urology, 50: 562, 1997 
10 Naughton, C. K., Miller, D. C., Mager, D. E., Ornstein, D. K. and Catalona, 
W. J.: A prospective randomized trial comparing 6 versus 12 prostate biopsy 
cores: impact on cancer detection. J Urol, 164: 388, 2000 
11  Kirby, R. S.: Pre-treatment staging of prostate cancer: recent advances and 
future prospects. Prostate Cancer Prostatic Dis, 1: 2, 1997 
12 Ragde, H., Kenny, G. M., Murphy, G. P. and Landin, K.: 
Transrectalultrasound microbubble contrast angiography of the prostate. 
Prostate, 32: 279, 1997 
13 Bogers, H. A., Sedelaar, J. P., Beerlage, H. P., de la Rosette, J. J., Debruyne, 
F. M., Wijkstra, H. et al: Contrast-enhanced threedimensional power 
Doppler angiography of the human prostate: correlation with biopsy 
outcome. Urology, 54: 97, 1999 
 
 
54 
 14.Frauscher, F., Klauser, A., Volgger, H., Halpern, E. J., Pallwein,L., Steiner, H. 
et al: Comparison of contrast enhanced color Doppler targeted biopsy with 
conventional systematic biopsy:impact on prostate cancer detection. J Urol, 167: 
1648, 2002. 
15. Loch T: Urologic imaging for localized prostatecancer in 2007. World J Urol 
2007; 25: 121. 
16. Aigner F, Pallwein L, Mitterberger M et al: Contrast-enhanced ultrasonography 
using cadence contrast pulse sequencing technology for targeted biopsy of the 
prostate. BJU Int 2009; 103:458. 
17. Wink M, Frauscher F, Cosgrove D et al: Contrastenhancedultrasound and 
prostate cancer; a multicenter European research coordination project.EurUrol 
2008; 58: 982. 
 
 
  
 
 
55 
                                         APPENDIX I 
INFORMED CONSENT FORM 
Title of the study:   
“COMPARISON OF CONTRAST ENHANCED COLOR DOPPLER 
TARGETED BIOPSY TO CONVENTIONAL SYSTEMATIC BIOPSY IN 
CARCINOMA PROSTATE” 
Name of the Participant:  
Name of the Principal (Co-Investigator): 
                   DR.J.INDUJA 
Name of the Institution:  Rajiv Gandhi Govt General Hospital, Chennai – 3 
 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been answered. 
I am over 18 years of age and, exercising my free power of choice, hereby give my 
consent to be included as a participant in “COMPARISON OF CONTRAST 
ENHANCED COLOR DOPPLER TARGETED BIOPSY TO 
CONVENTIONAL SYSTEMATIC BIOPSY IN CARCINOMA PROSTATE” 
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1. I have read and understood this consent form and the information provided to 
me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past 3 months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately 
if I suffer unusual symptoms. 
8. I have not participated in any research study within the past 6 month(s) 
10. I am aware of the fact that I can opt out of the study at any time without having 
to give any reason and this will not affect my future treatment in this hospital.  
11. I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without my consent. 
 
 
57 
12. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC. I understand that they are publicly presented. 
13. I have understand that my identity will be kept confidential if my data are 
publicly presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document. 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
Name _________________________ Signature_________________ 
Date________________ 
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Name and Signature of impartial witness (required for illiterate patients): 
Name _________________________ Signature_________________ 
Date________________ 
 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name _________________________ Signature_________________ 
Date________________ 
For Children being enrolled in research: 
Whether child’s assent was asked: Yes / No (Tick one) 
[If the answer to be above question is yes, write the following phrase: 
You agree with the manner in which assent was asked for from your child and 
given by your child. You agree to have your child take part in this study]. 
[If answer to be above question No, give reason (s) 
:___________________________________. 
Although your child did not or could not give his or her assent, you agree to your 
child’s Participation in this study. 
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Name and Signature of / thumb impression of the participant’s parent(s) (or legal 
representative) 
Name _________________________ Signature_________________ 
Date________________ 
 
Name _________________________ Signature_________________ 
Date________________ 
 
Name and Signature of impartial witness (required for parents of participant child 
illiterate): 
Name _________________________ Signature_________________ 
Date________________ 
Address and contact number of the impartial witness: 
__________________________________ 
Name and Signature of the investigator or his representative obtaining consent: 
Name _________________________ Signature_________________ 
Date________________ 
 
 
60 
 
 
 
61 
                                                Appendix II 
PROFORMA 
 
Title 
“COMPARISON OF CONTRAST ENHANCED COLOR DOPPLER 
TARGETED BIOPSY TO CONVENTIONAL SYSTEMATIC BIOPSY IN 
CARCINOMA PROSTATE” 
Sl.No:                                                                    Date: 
    Name:                                                                    IP No: 
    Age/Sex: 
              Occupation:                                                       
Address: 
Presenting Complaints 
Duration                 : 
Others   : 
Past History 
Vital signs 
Pulse    :                          
    BP    : 
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Respiratory rate  : 
General Examination    
Built   : 
Anemia  : 
Per rectal Examination  
Lab finding- 
Urine routine 
Urine culture and sensitivity 
BT/CT 
Complete blood count 
Renal function test 
 Serum PSA level (ng/ml)- 
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Transrectal ultrasound: 
 
Prostate region Gray scale 
 
     Ultrasound contrast 
    (enhancement) 
Right base   
Left base   
Right medial mid portion   
Right lateral mid portion   
Left medial mid portion   
Left lateral mid portion   
Right apex   
Left apex   
 
HPE report  
Number of cores positive - conventional TRUS / contrast enhanced TRUS 
Gleason grade of each positive core 
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NAME 
AG
E 
SR
. 
PS
A 
DRE cont.enhancement 
NO.O
F 
POS. 
CORE
S 
GLEAS
ON  
GRADE 
SYSTEMATIC BIOPSY 
NO.O
F. 
POS. 
CORE
S 
gleas
on  
score 
              
rt. 
bas
e 
lt. 
bas
e 
rt.mi
d - 
med 
rt.mi
d- 
lat 
lt.mi
d- 
med 
lt.mi
d- 
lat 
rt. 
ape
x 
lt. 
ape
x     
paulraj 
65/
m 
21.
9 
NODUL
AR RT.LAT/LT.LAT 2 5+3 neg neg pos pos neg pos neg neg 3 3+2 
govindan 
78/
m 
16.
7 
NODUL
AR RT.MID GL 1 4+3 neg neg neg pos neg neg neg neg 1 3+3 
duraikannan 
70/
m 13 
NORMA
L 
RT.MID 
GL/LT.MID.GL 2 3+2 neg neg pos neg neg pos neg neg 2 3+2 
vellai 
65/
m 15 
NODUL
AR Lt.apex,mid gl 1 3+3 neg neg neg neg pos pos neg neg 2 3+2 
bahavandas 
46/
m 9.6 
NORMA
L lt.base 1 3+2 neg neg neg neg neg neg neg neg 0 0 
rathinavelu 
60/
m 4.6 
NODUL
AR rt.mid gl 1 4+3 neg neg pos neg neg neg neg neg 1 4+3 
subramani 
60/
m 
17.
6 
NORMA
L lt.apex 1 4+2 neg neg neg neg neg neg neg pos 0 3+2 
santhanam 
60/
m 0.9 
NODUL
AR neg 0 0 neg neg neg neg neg neg neg neg 0 0 
krishnan 
60/
m 
23.
3 
NODUL
AR lt.base/lt.mid 1 3+4 neg pos pos neg pos pos neg neg 4 3+3 
Ibrahim 
sheriff 
70/
m 16 
NODUL
AR lt.mid gl 1 3+4 neg neg neg neg neg neg neg neg 0 0 
Dheenadhaya
lan 
60/
m 6.2 
NORMA
L rt.apex 1 5+3 neg neg pos neg neg neg pos neg 2 3+4 
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kumar 
52/
m 0.6 
NODUL
AR 
RT.MID 
GL/LT.MID.GL 1 2+1 neg neg neg neg pos neg neg neg 1 2+1 
boopalan 
55/
m 
18.
2 
NODUL
AR lt.base 1 3+2 neg pos neg neg neg neg neg neg 1 3+2 
dakshinamoo
rthi 
60/
m 
24.
1 
NODUL
AR lt.mid/lt.base 2 3+4 neg pos neg neg pos pos neg neg 3 3+4 
arjunan 
55/
m 6.7 
NORMA
L rt.apex 0 BPH neg neg neg neg neg neg neg neg 0 0 
kailasam 
69/
m 4.2 
NODUL
AR lt.mid/lt.base 0 PIN neg neg neg neg neg neg neg neg 0 0 
natarajan 
72/
m 
24.
8 
NODUL
AR lt.mid/apex/base 3 4+3 neg pos neg neg pos neg neg pos 3 3+3 
dhamodharan 
60/
m 
17.
6 
NODUL
AR rt.apex 1 4+3 neg neg neg pos neg neg pos neg 2 4+3 
munusamy 
70/
m 
9.2
9 
NORMA
L lt.mid 1 2+1 neg neg neg neg neg neg neg neg 0 0 
dhayalan 
53/
m 
5.4
7 
NODUL
AR rt.med 1 3+2 neg neg neg pos neg neg neg neg 1 2+1 
vaiyapuri 
76/
m 
12.
8 
NODUL
AR rt.base/mid gl 1 4+3 neg neg pos neg neg neg neg neg 1 3+2 
arumugam 
63/
m 
13.
3 
NODUL
AR lt.apex 1 3+3 neg neg neg neg neg pos neg neg 1 3+3 
abdul lateef 
62/
m 
23.
1 
NODUL
AR lt.mid gl 1 4+3 neg neg neg neg pos neg neg neg 1 4+3 
krishnamoort
hi 
75/
m 9.6 
NORMA
L rt.mid 0 0 neg neg neg neg neg neg neg neg 0 0 
thangaraj 
41/
m 16 
NODUL
AR lt.mid/rt.base 1 3+2 pos neg neg neg neg neg neg neg 1 3+2 
        35 26                   30   
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                                         APPENDIX I 
INFORMED CONSENT FORM 
Title of the study:   
“COMPARISON OF CONTRAST ENHANCED COLOR DOPPLER 
TARGETED BIOPSY TO CONVENTIONAL SYSTEMATIC BIOPSY IN 
CARCINOMA PROSTATE” 
Name of the Participant:  
Name of the Principal (Co-Investigator): 
                   DR.J.INDUJA 
Name of the Institution:  Rajiv Gandhi Govt General Hospital, Chennai – 3 
 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been answered. 
I am over 18 years of age and, exercising my free power of choice, hereby give my 
consent to be included as a participant in “COMPARISON OF CONTRAST 
ENHANCED COLOR DOPPLER TARGETED BIOPSY TO 
CONVENTIONAL SYSTEMATIC BIOPSY IN CARCINOMA PROSTATE” 
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1. I have read and understood this consent form and the information provided to 
me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past 3 months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately 
if I suffer unusual symptoms. 
8. I have not participated in any research study within the past 6 month(s) 
10. I am aware of the fact that I can opt out of the study at any time without having 
to give any reason and this will not affect my future treatment in this hospital.  
11. I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without my consent. 
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12. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC. I understand that they are publicly presented. 
13. I have understand that my identity will be kept confidential if my data are 
publicly presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document. 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
Name _________________________ Signature_________________ 
Date________________ 
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Name and Signature of impartial witness (required for illiterate patients): 
Name _________________________ Signature_________________ 
Date________________ 
 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name _________________________ Signature_________________ 
Date________________ 
For Children being enrolled in research: 
Whether child’s assent was asked: Yes / No (Tick one) 
[If the answer to be above question is yes, write the following phrase: 
You agree with the manner in which assent was asked for from your child and 
given by your child. You agree to have your child take part in this study]. 
[If answer to be above question No, give reason (s) 
:___________________________________. 
Although your child did not or could not give his or her assent, you agree to your 
child’s Participation in this study. 
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Name and Signature of / thumb impression of the participant’s parent(s) (or legal 
representative) 
Name _________________________ Signature_________________ 
Date________________ 
 
Name _________________________ Signature_________________ 
Date________________ 
 
Name and Signature of impartial witness (required for parents of participant child 
illiterate): 
Name _________________________ Signature_________________ 
Date________________ 
Address and contact number of the impartial witness: 
__________________________________ 
Name and Signature of the investigator or his representative obtaining consent: 
Name _________________________ Signature_________________ 
Date________________ 
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                                                Appendix II 
PROFORMA 
 
Title 
“COMPARISON OF CONTRAST ENHANCED COLOR DOPPLER 
TARGETED BIOPSY TO CONVENTIONAL SYSTEMATIC BIOPSY IN 
CARCINOMA PROSTATE” 
Sl.No:                                                                    Date: 
    Name:                                                                    IP No: 
    Age/Sex: 
              Occupation:                                                       
Address: 
Presenting Complaints 
Duration                 : 
Others   : 
Past History 
Vital signs 
Pulse    :                          
    BP    : 
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Respiratory rate  : 
General Examination    
Built   : 
Anemia  : 
Per rectal Examination  
Lab finding- 
Urine routine 
Urine culture and sensitivity 
BT/CT 
Complete blood count 
Renal function test 
 Serum PSA level (ng/ml)- 
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Transrectal ultrasound: 
 
Prostate region Gray scale 
 
     Ultrasound contrast 
    (enhancement) 
Right base   
Left base   
Right medial mid portion   
Right lateral mid portion   
Left medial mid portion   
Left lateral mid portion   
Right apex   
Left apex   
 
HPE report  
Number of cores positive - conventional TRUS / contrast enhanced TRUS 
Gleason grade of each positive core 
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NAME 
AG
E 
SR
. 
PS
A 
DRE cont.enhancement 
NO.O
F 
POS. 
CORE
S 
GLEAS
ON  
GRADE 
SYSTEMATIC BIOPSY 
NO.O
F. 
POS. 
CORE
S 
gleas
on  
score 
              
rt. 
bas
e 
lt. 
bas
e 
rt.mi
d - 
med 
rt.mi
d- 
lat 
lt.mi
d- 
med 
lt.mi
d- 
lat 
rt. 
ape
x 
lt. 
ape
x     
paulraj 
65/
m 
21.
9 
NODUL
AR RT.LAT/LT.LAT 2 5+3 neg neg pos pos neg pos neg neg 3 3+2 
govindan 
78/
m 
16.
7 
NODUL
AR RT.MID GL 1 4+3 neg neg neg pos neg neg neg neg 1 3+3 
duraikannan 
70/
m 13 
NORMA
L 
RT.MID 
GL/LT.MID.GL 2 3+2 neg neg pos neg neg pos neg neg 2 3+2 
vellai 
65/
m 15 
NODUL
AR Lt.apex,mid gl 1 3+3 neg neg neg neg pos pos neg neg 2 3+2 
bahavandas 
46/
m 9.6 
NORMA
L lt.base 1 3+2 neg neg neg neg neg neg neg neg 0 0 
rathinavelu 
60/
m 4.6 
NODUL
AR rt.mid gl 1 4+3 neg neg pos neg neg neg neg neg 1 4+3 
subramani 
60/
m 
17.
6 
NORMA
L lt.apex 1 4+2 neg neg neg neg neg neg neg pos 0 3+2 
santhanam 
60/
m 0.9 
NODUL
AR neg 0 0 neg neg neg neg neg neg neg neg 0 0 
krishnan 
60/
m 
23.
3 
NODUL
AR lt.base/lt.mid 1 3+4 neg pos pos neg pos pos neg neg 4 3+3 
Ibrahim 
sheriff 
70/
m 16 
NODUL
AR lt.mid gl 1 3+4 neg neg neg neg neg neg neg neg 0 0 
Dheenadhaya
lan 
60/
m 6.2 
NORMA
L rt.apex 1 5+3 neg neg pos neg neg neg pos neg 2 3+4 
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kumar 
52/
m 0.6 
NODUL
AR 
RT.MID 
GL/LT.MID.GL 1 2+1 neg neg neg neg pos neg neg neg 1 2+1 
boopalan 
55/
m 
18.
2 
NODUL
AR lt.base 1 3+2 neg pos neg neg neg neg neg neg 1 3+2 
dakshinamoo
rthi 
60/
m 
24.
1 
NODUL
AR lt.mid/lt.base 2 3+4 neg pos neg neg pos pos neg neg 3 3+4 
arjunan 
55/
m 6.7 
NORMA
L rt.apex 0 BPH neg neg neg neg neg neg neg neg 0 0 
kailasam 
69/
m 4.2 
NODUL
AR lt.mid/lt.base 0 PIN neg neg neg neg neg neg neg neg 0 0 
natarajan 
72/
m 
24.
8 
NODUL
AR lt.mid/apex/base 3 4+3 neg pos neg neg pos neg neg pos 3 3+3 
dhamodharan 
60/
m 
17.
6 
NODUL
AR rt.apex 1 4+3 neg neg neg pos neg neg pos neg 2 4+3 
munusamy 
70/
m 
9.2
9 
NORMA
L lt.mid 1 2+1 neg neg neg neg neg neg neg neg 0 0 
dhayalan 
53/
m 
5.4
7 
NODUL
AR rt.med 1 3+2 neg neg neg pos neg neg neg neg 1 2+1 
vaiyapuri 
76/
m 
12.
8 
NODUL
AR rt.base/mid gl 1 4+3 neg neg pos neg neg neg neg neg 1 3+2 
arumugam 
63/
m 
13.
3 
NODUL
AR lt.apex 1 3+3 neg neg neg neg neg pos neg neg 1 3+3 
abdul lateef 
62/
m 
23.
1 
NODUL
AR lt.mid gl 1 4+3 neg neg neg neg pos neg neg neg 1 4+3 
krishnamoort
hi 
75/
m 9.6 
NORMA
L rt.mid 0 0 neg neg neg neg neg neg neg neg 0 0 
thangaraj 
41/
m 16 
NODUL
AR lt.mid/rt.base 1 3+2 pos neg neg neg neg neg neg neg 1 3+2 
        35 26                   30   
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